JPMorgan’s Asset Management Builds $2.93B Eli Lilly Stake in GLP-1 Push
JPMorgan’s investment arm disclosed a $2.93 billion position in Eli Lilly, becoming its largest new stake in the latest quarter. Overall fund turnover reached 15.6% with a 26.3% concentration in top 10 holdings, signaling a strategic shift toward GLP-1 health care leaders.
1. Investment Arm Discloses Eli Lilly Position
JPMorgan’s asset management division reported a $2.93 billion equity position in Eli Lilly in its latest portfolio filing, making it the largest new stake among 638 fresh purchases for the quarter.
2. Portfolio Composition and Turnover
The firm’s managed assets totaled $1.59 trillion, with inflows equal to 6.26% of total market value. Top 10 holdings concentration rose to 26.3%, overall turnover reached 15.6%, and positions were added in 2,643 stocks while 605 were sold out.
3. GLP-1 Growth Drives Allocation Strategy
The allocation reflects bullish expectations for GLP-1 products, with Eli Lilly posting $19.3 billion in Q4 sales (up 43% year-over-year), $7.4 billion from Mounjaro and $4.3 billion from Zepbound, as obesity-drug market projections near $100 billion by 2030.